Studies involving FGFR3 activated bladder cancer cell lines show major inhibition of p-ERK but not p-AKT following FGFR inhibitor treatment, which suggests that the MAPK pathway could be the major downstream signaling pathway that is activated [69, 95, 96]. This evidence concerns the gene MAPK1 and urinary bladder cancer.